Skin Cancer & Melanoma

Intensive surveillance and surgical resection for hepatic metastases from uveal melanoma improved long-term remission in a retrospective study.

Pembrolizumab administered before surgery in patients with desmoplastic melanoma led to high pathologic complete response rates in the SWOG S1512 trial.

A phase 3 trial of iSCIB1+, a novel cancer vaccine, assessing patients with advanced melanoma has been cleared by the FDA.

Updated data from the 5-year analysis of KEYNOTE-942 of mRNA-4157/pembrolizumab in high-risk melanoma showed a maintained benefit.

Investigators are currently assessing treatment with Alpha DaRT among those with recurrent CSCC as part of the ReSTART trial.

Sorafenib improved the median progression-free survival compared with placebo among patients with metastatic uveal melanoma in the STREAM study.

Updated results from the phase 1 CK-301-101 trial support the updated label for cosibelimab in this cutaneous squamous cell carcinoma population.

At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Biomarker analyses and real-world comparisons to refine patient selection are ongoing in the phase 2 PLUME trial.

The 24-month RFS rates were 95.1%, 81.2%, 69.4%, and 48.4% in patients with stage III melanoma who experienced a pCR, near pCR, pPR, pNR, respectively.

The agency has set a PDUFA date of April 10, 2026, for the decision on RP1 plus nivolumab in patients with previously treated advanced melanoma.

A novel cancer vaccine, IO102-IO103, combined with pembrolizumab, showed promising results in improving PFS for advanced melanoma.

Cemiplimab showed comparable rates of second primary tumors and improved disease-free survival in high-risk cutaneous squamous cell carcinoma patients.

Nine-year final results from the CheckMate 238 trial demonstrated that adjuvant nivolumab significantly improved time to second disease progression.

BNT111 combined with cemiplimab showed promising efficacy in treating PD-(L) PD-L1-relapsed/refractory melanoma, achieving an 18.1% objective response rate.

Single-agent pembrolizumab achieved an ORR of 89%, with a 37% CR rate, in patients with advanced desmoplastic melanoma in the phase 2 SWOG S1512 trial.

Data from a phase 1/1b trial showed that WTX-124 achieved clinically meaningful activity in those with advanced melanoma following SOC immunotherapy.

Findings from the phase 3 C-POST trial support the FDA approval of cemiplimab in this cutaneous squamous cell carcinoma population.

Pathologists should try to educate oncologists about the sensitivity and specificity of assays to help optimize care plans, said David Rimm, MD, PhD.

Adjuvanted imsapepimut and etimupepimut plus pembrolizumab did not yield a statistically significant PFS improvement as treatment for advanced melanoma.

Artificial intelligence used in conjunction with clinicians may help standardize and expedite pathology workflows and reduce variability in TIL scoring.

An 80% disease metastasis–free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

Clinicians discuss the best treatment options for a 46-year-old woman diagnosed with BRAF+ melanoma.

Two studies were recently published that validated the use of the DecisionDx-SCC test as a tool for the treatment of cutaneous squamous cell carcinoma.